Stock analysis, trade plans, and proprietary indicators by Trend Edge.
ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases. The company offers hepatic-targeted programs, including Agazisiran, a complement factor B (CFB) program that represents a pipeline-in-a-product opportunity, where a single therapeutic candidate has the potential to address multiple indications; Onvuzosiran, a clinical program for the p… Read full Trend Edge analysis →
| Current Price | $13.80 |
|---|---|
| Market Cap | $1.47B |
| Float | 49.4M |
| Shares Outstanding | 110.7M |
| Price/Sales (TTM) | 240.20 |
| vs. Analyst Target | +148.2% to analyst PT |
| Operating Margin (TTM) | -4006.84% |
| Revenue (TTM) | $6.1M |
| Dividend Rate | None |
| Analyst Target Price | $34.25 (5 analysts) |
| Year | Revenue | Net Income | Gross Profit | EBITDA |
|---|---|---|---|---|
| 2024 | N/A | -$46.4M | N/A | -$56.7M |
| 2025 | $3.4M | -$73.1M | N/A | -$86.0M |
| Quarter | Revenue | Net Income |
|---|---|---|
| Mar 2025 | N/A | -$15.6M |
| Jun 2025 | $208,000 | -$18.1M |
| Mar 2026 | $2.1M | -$22.7M |
| Jun 2026 | $746,000 | -$25.8M |
| Insider Ownership | 41.8% |
|---|---|
| Institutional Ownership | 49.2% |
| Short Float | 3.9% |
Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.
| Timeframe | SMA | Value | Trend Context |
|---|---|---|---|
| Weekly | 10-Week SMA | $0.00 | Near-term / short-term trend |
| Weekly | 40-Week SMA | $0.00 | Medium-term trend |
| Weekly | 80-Week SMA | $0.00 | Cyclical trend (business cycle) |
| Weekly | 200-Week SMA | $0.00 | Secular trend (multi-year) |
| Monthly | 10-Month SMA | $0.00 | Near-term monthly trend |
| Monthly | 20-Month SMA | $0.00 | Medium-term monthly trend |
| Monthly | 40-Month SMA | $0.00 | Secular monthly trend |
Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.
Volume shelf data not available.
| Timeframe | Avg Return | Median | Win Rate | Best | Worst |
|---|---|---|---|---|---|
| Gap | N/A | N/A | N/A | N/A | N/A |
| 1 Day | N/A | N/A | N/A | N/A | N/A |
| 1 Week | N/A | N/A | N/A | N/A | N/A |
| 2 Weeks | N/A | N/A | N/A | N/A | N/A |
| 1 Month | N/A | N/A | N/A | N/A | N/A |
Insufficient historical data for monthly seasonality analysis (requires 7+ years of data).
Institutional holder breakdown coming soon.
Total institutional ownership: 49.2%
Total insider ownership: 41.8%
Founder-led management: Zhen Li (President & Chief Executive Officer)
| Total Filings | 5 |
|---|---|
| Net Value | +N/A |
| Net Shares Change | 77,576,925 |
| % of Float | 157.0% |
| C-Suite Filings | 0 |
| Clusters Detected | 1 |
| Name | Title | Net Value | Filings | Activity |
|---|---|---|---|---|
| SR ONE CAPITAL MANAGEMENT, LLC | +$27.2M | 1 | 1 buy | |
| George Simeon | +$27.2M | 1 | 1 buy | |
| ORBIMED ADVISORS LLC | +$16.1M | 1 | 1 buy | |
| GORDON CARL L | +$16.1M | 1 | 1 buy | |
| Chimovits Erez | +$1.0M | 1 | 1 buy |
| Period | Filings | Insiders | Net Value | Seniority |
|---|---|---|---|---|
| 2026-09-29 – 2026-09-30 | 5 | 5 | +$87.7M |
| Date | Insider | Title | Net Value | Price After |
|---|---|---|---|---|
| 2026-09-30 | ORBIMED ADVISORS LLC | +$16.1M | Transaction at $17.00, now -18.8% | |
| 2026-09-30 | GORDON CARL L | +$16.1M | Transaction at $17.00, now -18.8% | |
| 2026-09-29 | SR ONE CAPITAL MANAGEMENT, LLC | +$27.2M | Transaction at $17.00, now -18.8% | |
| 2026-09-29 | George Simeon | +$27.2M | Transaction at $17.00, now -18.8% | |
| 2026-09-30 | Chimovits Erez | +$1.0M | Transaction at $17.00, now -18.8% |
Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for ADARx Pharmaceuticals, Inc. Common Stock (ADRX) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).
AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.
Get the full AI Consult analysis for ADRX on Trend Edge →